enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Pfizer's bladder cancer therapy meets main goal in late-stage ...

   www.aol.com/news/pfizers-bladder-cancer-therapy...

   The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...

3. Bladder cancer - Wikipedia

   en.wikipedia.org/wiki/Bladder_cancer

   Bladder cancer is the abnormal growth of ... The 2022 standard of care for metastatic bladder cancer is combination treatment with the chemotherapy drugs ...

4. Transitional cell carcinoma - Wikipedia

   en.wikipedia.org/wiki/Transitional_cell_carcinoma

   Treatment for localized stage transitional cell carcinomas is surgical resection of the tumor, but recurrence is common. Some patients are given mitomycin into the bladder either as a one-off dose in the immediate post-operative period (within 24 hrs) or a few weeks after the surgery as a six dose regimen.

5. Nadofaragene firadenovec - Wikipedia

   en.wikipedia.org/wiki/Nadofaragene_firadenovec

   The safety and effectiveness of nadofaragene firadenovec was evaluated in a multicenter clinical study (Study CS-003 (NCT02773849)) that included 157 participants with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response.

6. US FDA approves ImmunityBio's bladder cancer therapy - AOL

   www.aol.com/news/u-fda-approves-immunitybios...

   In an 83-patient arm of a late-stage study, the combination treatment showed a complete disappearance of tumors in 71% of patients, with a median duration of response of 24.1 months.

7. CG Oncology Touts Encouraging Data From Late-Stage Study Of ...

   www.aol.com/finance/cg-oncology-touts...

   Additionally, 97.3% of patients were free from progression to Muscle Invasive Bladder Cancer (MIBC) at 12 months.” No Grade 3 or greater treatment-related adverse events (TRAEs) or deaths were ...